Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression (TranS-C+BL)
Launched by UNIVERSITY OF PITTSBURGH · May 6, 2025
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
The clinical trial titled "Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression" is investigating a new way to help teenagers who are struggling with depression and sleep problems, particularly focusing on those at higher risk for suicidal thoughts and behaviors. This is important because suicide is a leading cause of death among young people, and Black youth face even greater risks. The study aims to see if improving sleep can help reduce these risks and provide a tailored approach for adolescents.
To participate, teens aged 12 to 18 with moderate to severe depression and significant sleep disturbances may be eligible. Participants will receive support from a Sleep Therapist through telehealth sessions and will use a special watch to track their sleep. They will also keep a daily sleep diary and wear bright light glasses in the morning and blue light-blocking glasses in the evening to help regulate their sleep patterns. This innovative approach not only focuses on improving sleep but also provides personalized feedback based on their sleep data. If you or someone you know is interested in participating, this trial could offer a new way to support mental health through better sleep.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adolescents (12-18)
- • Current moderate to severe depression as measured by the PHQ-9M with a total score of greater than or equal to 11
- • Current clinically significant sleep disturbance measured by the PHQ-9-M sleep item greater than or equal to 2.
- • English language fluency and literacy sufficient to engage in study protocol.
- Exclusion Criteria:
- • Evidence of obstructive sleep apnea,
- • Evidence of restless legs syndrome
- • Evidence of psychosis
- • Evidence of bipolar disorder
- • Evidence of a developmental disability precluding comprehension of study procedures per electronic health record and eligibility screening.
About University Of Pittsburgh
The University of Pittsburgh is a leading research institution known for its commitment to advancing medical science and improving patient care through innovative clinical trials. With a robust infrastructure for research and a multidisciplinary approach, the university fosters collaboration among experts in various fields, facilitating the development of novel therapies and interventions. Its clinical trial programs emphasize ethical standards, patient safety, and the integration of cutting-edge technology, making the University of Pittsburgh a pivotal contributor to the landscape of clinical research and a trusted partner in the pursuit of health advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Pittsburgh, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Tina Goldstein, Ph.D
Principal Investigator
University of Pittsburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported